NCT04890236 2025-01-20
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Emory University
Phase EARLY_PHASE1 Completed
Clinical Trials
5 trialsNCT01029366 2023-06-22
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
Phase 1 Completed
NCT02030834 2023-06-22
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
University of Pennsylvania
Phase 2 Completed
NCT02529813 2022-06-30
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01626495 2020-03-23
Pedi CART19
University of Pennsylvania
Phase 1/2 Completed